Question explored with the scientific record
Side effects of Clozapine
Clozapine is a powerful drug for a devastating illness, but its side effect profile is severe and the evidence shows monitoring is routinely inadequate.
The evidence here is not from the manufacturer. It comes from independent pharmacovigilance databases, NHS audits, and international expert panels. That makes it more reliable than industry-funded trials, but it is still observational data, not a controlled experiment.
The most dangerous side effect is myocarditis (inflammation of the heart muscle). A 2025 analysis of the WHO global database found clozapine was the second most reported drug for myocarditis, with 5,353 reports out of 35,017 top-drug reports [1]. That is 15% of all myocarditis reports for the top ten drugs. The median time to onset was just 1 day [1]. A 2026 NHS audit of 180 patients found that 43% developed tachycardia in the first four weeks, and 7% had to stop clozapine due to suspected cardiac complications [2]. Despite this, only 4% of patients had the recommended weekly troponin and CRP monitoring [2]. The system is not watching for the harm it knows is coming.
| Side Effect | How Common | Source |
|---|---|---|
| Myocarditis (reported) | 15% of top-drug reports | [1] |
| Tachycardia (first 4 weeks) | 43% of patients | [2] |
| Discontinuation for cardiac reasons | 7% of patients | [2] |
| Seizures (reported) | 9% of all clozapine ADRs | [5] |
| Agranulocytosis | 0.7-0.8% incidence | [6] |
Agranulocytosis (dangerously low white blood cells) is the other well-known risk, occurring in about 0.7-0.8% of patients [6]. A 2002 Hungarian study of 750 patients found 7 cases of granulocytopenia and 2 of agranulocytosis, all reversible with monitoring [4]. But the mortality from clozapine-associated agranulocytosis in large datasets was around 0.016-0.017% [6]. The risk is real but manageable with strict blood monitoring.
The 2025 international consensus recommended waiting at least 4 weeks after an mRNA vaccine before starting clozapine, and at least 2-3 weeks after a viral infection, to avoid additive myocarditis risk [3]. This is a rare admission from the establishment that multiple inflammatory triggers can stack.
My call: clozapine can be life-saving for treatment-resistant schizophrenia, but the cardiac risks are high and the monitoring that is supposed to protect patients is not happening in practice. The burden is on the prescriber to prove they are doing weekly troponin and CRP, not on the patient to survive without it. Confidence: high for the existence and severity of the risks, moderate for the exact rates (which vary by population and reporting system).
Sources used 6
-
Top 10 drugs most frequently associated with adverse events of myocarditis and pericarditis
Using the WHO global pharmacovigilance database (VigiBase) from 1968–2024, this study identified the top drugs most frequently reported with myocarditis and pericarditis, using disproportionality metrics IC025 and ROR to reveal five drugs common to both conditions (clozapine, me…
DOI: 10.1038/s41598-025-13234-6 -
Myocarditis monitoring during clozapine initiation: audit of practice in an NHS trust
A retrospective audit of 180 clozapine initiations in one NHS trust found baseline ECG in 80% but almost no routine troponin/CRP monitoring; tachycardia and cardiac-related early discontinuations were common.
DOI: 10.1192/bjo.2026.12079 -
Multidisciplinary consensus on prevention, screening and monitoring of clozapine-associated myocarditis and clozapine rechallenge after myocarditis
First multidisciplinary Delphi consensus established diagnostic criteria for clozapine-associated myocarditis, minimum and enhanced monitoring algorithms for clozapine initiation, and a rechallenge protocol after myocarditis based on expert agreement.
DOI: 10.1192/bjp.2025.89 -
Agranulocytosis during clozapine therapy
A retrospective analysis from Hungary describing the incidence, reversibility, and management of clozapine-related granulocytopenia and agranulocytosis in 750 patients over 15 years, including three illustrative cases and a discussion of monitoring and reinstitution of therapy.
DOI: 10.1016/s0278-5846(01)00256-1 -
Seizure risk associated with neuroactive drugs: Data from the WHO adverse drug reactions database
This study investigates the association between neuroactive drugs and the occurrence of seizures using data from the WHO adverse drug reactions database, revealing that certain antidepressants and antipsychotics are more frequently linked to convulsive adverse drug reactions.
DOI: 10.1016/j.seizure.2009.11.005 -
Drug-Induced Neutropenia and Agranulocytosis
A Russian-language review summarizing the epidemiology, risk factors, mechanisms, clinical presentation, diagnosis, prevention, and treatment of drug-induced neutropenia and agranulocytosis, with emphasis on diverse offending drugs (notably clozapine) and the role of growth fact…
DOI: 10.30895/2312-7821-2020-8-3-109-122